30-Month Stay: How Patent Litigation Delays Generic Drug Approval
The 30-month stay under the Hatch-Waxman Act delays generic drug approval when patent lawsuits are filed. It's meant to balance innovation and access, but in practice, it often extends market monopolies by years - costing patients billions.